The impact of skin damage due to cutaneous lupus on quality of life

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 315-321

  Verma, S M ^a,b   Okawa, J ^a,b   Propert, K J ^b   Werth, V P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; CHILD; CICATRIX; CONTINENTAL POPULATION GROUPS; EMOTIONS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; PIGMENTATION DISORDERS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

EID: 84894263264     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12653     Document Type: Article

References (22)

1. Durosaro O, Davis MD, Reed KB, Rohlinger AL,. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009; 145: 249-53.
2. Tebbe B, Orfanos CE,. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96-104.
3. Tan EM, Cohen AS, Fries JF, et al,. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
4. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
5. Fernández M, Alarcõn GS, Calvo-Alén J, et al,. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57: 576-84.
6. Moldovan I, Katsaros E, Carr FN, et al,. The patient reported outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a southern California lupus cohort. Lupus 2011; 20: 1285-92.
7. Pons-Estel GJ, Alarcõn GS, González LA, et al,. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res (Hoboken) 2010; 62: 393-400.
8. Ferraz LB, Almeida FA, Vasconcellos MR, et al,. The impact of lupus erythematosus cutaneous on the quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res 2006; 15: 565-70.
9. Albrecht J, Taylor L, Berlin JA, et al,. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
10. Klein R, Moghadam-Kia S, LoMonico J, et al,. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011; 64: 849-58.
11. Gaines E, Bonilla-Martinez Z, Albrecht J, et al,. Quality of life and disease severity in a cutaneous lupus erythematosus pilot study. Arch Dermatol 2008; 144: 1061-2.
12. Bonilla-Martinez ZL, Albrecht J, Troxel AB, et al,. The Cutaneous Lupus Erythematosus Disease Area and Severity Index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol 2008; 144: 173-80.
13. Krathen MS, Dunham J, Gaines E, et al,. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008; 59: 338-44.
14. Moghadam-Kia S, Chilek K, Gaines E, et al,. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009; 145: 255-60.
15. Piette EW, Foering KP, Chang AY, et al,. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148: 317-22.
16. Foering K, Goreshi R, Klein R, et al,. Prevalence of self-report photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol 2012; 66: 220-8.
17. Linthorst Homan MW, Spuls PI, de Korte J, et al,. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61: 411-20.
18. Purvisha P, Werth V,. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20: 373-85.
19. Klein R, Moghadam-Kia S, LoMonico J, et al,. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011; 147: 203-8.
20. Chren M-M, Lasek RJ, Flocke SA, Zyzanski SJ,. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133: 1433-40.
21. Chren MM, Lasek RJ, Quinn LM, et al,. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-13.
22. Samponga F, Raskovic D, Guerra L, et al,. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol 2008; 159: 351-9.